« BE - Du Pont et al v. Mylan / Losartan SPC (first instance) | Main | UK - Actavis UK Limited v Novartis AG »



Feed You can follow this conversation by subscribing to the comment feed for this post.

It is important to note that the EBA did not say that all diagnostic imaging methods using contrast agents are not patentable.

The EBA's statement on exclusion from patentability is rather limited, as it only concerns methods encompassing an invasive step representing a substantial physical intervention on the body which requires professional medical expertise to be carried out and which entails a substantial health risk even when carried out with the required professional care and expertise.

The comments to this entry are closed.


EPLAW Patent Blog sponsors:

Enter your email address:

Delivered by FeedBurner